ADCT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

18.33M

+8.4%

-0.290

-0%

19.65M

-14.69%

-0.275

-23.61%

19.95M

+5.9%

-0.275

-45%

Estimates Revision

The market is revising Downward the revenue expectations for ADC Therapeutics SA (ADCT) for FY2025, with the revenue forecasts being adjusted by -3.21% over the past three months. During the same period, the stock price has changed by -17.19%.

Revenue Estimates for FY2025

Revise Downward

-3.21%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.71%

In Past 3 Month

Stock Price

Go Down

-17.19%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

7.33

High

10.00

Current: 0.000

Low

5.00

Averages

7.33

High

10.00

H.C. Wainwright

Robert Burns

Buy

downgrade

$8 -> $7

2025-10-16

Reason

H.C. Wainwright

Robert Burns

Price Target

$8 -> $7

2025-10-16

downgrade

Buy

Reason

H.C. Wainwright analyst Robert Burns lowered the firm's price target on ADC Therapeutics to $7 from $8 and keeps a Buy rating on the shares. The firm reduced the price target after factoring in the private placement financing.

RBC Capital

Gregory Renza

Outperform

downgrade

$8 -> $5

2025-06-21

Reason

RBC Capital

Gregory Renza

Price Target

$8 -> $5

2025-06-21

downgrade

Outperform

Reason

RBC Capital analyst Gregory Renza lowered the firm's price target on ADC Therapeutics to $5 from $8 but keeps an Outperform rating on the shares. The firm says the company's high efficacy for Zynlonta in DLBCL gives it confidence in its likelihood to show clinically meaningful benefits in the 2nd line LOTIS-5 study, unlocking an additional $200M+ U.S. sales opportunity, the analyst tells investors in a research note. RBC adds that ADC shares are undervalued on the balance of a largely de-risked asset with multiple expansion opportunities that can reaccelerate growth.

Guggenheim

Buy

maintain

$7 -> $10

2025-06-13

Reason

Guggenheim

Price Target

$7 -> $10

2025-06-13

maintain

Buy

Reason

Guggenheim raised the firm's price target on ADC Therapeutics to $10 from $7 and keeps a Buy rating on the shares after the company released an update on their Phase 1b LOTIS-7 study of Zynlonta plus glofitamab as part of the EHA embargo lift. ADC also announced a $100M private placement financing intended to support Zynlonta's ongoing clinical programs and commercialization in earlier line DLBCL, as well as a restructuring comprising a 30% reduction in force and closure of UK operations, notes the analyst, who is updating the firm's estimates for all of these events.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

2025-03-31

Reason

HC Wainwright & Co.

Robert Burns

Price Target

2025-03-31

Reiterates

Strong Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Maintains

$10 → $7

2025-03-31

Reason

Guggenheim

Michael Schmidt

Price Target

$10 → $7

2025-03-31

Maintains

Strong Buy

Reason

Guggenheim lowered the firm's price target on ADC Therapeutics to $7 from $10 and keeps a Buy rating on the shares. Q4 results were largely consistent with prior disclosures, though Zynlonta sales of $16.4M came in below Street consensus, the analyst tells investors. The firm is updating its model to reflect a slightly more conservative timeline for potential Zynlonta label expansion into second-line Diffuse Large B-Cell Lymphoma as well as Q4 financial results.

Cantor Fitzgerald

Eric Schmidt

Buy

Reiterates

n/a

2025-03-07

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

n/a

2025-03-07

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for ADC Therapeutics SA (ADCT.N) is -3.13, compared to its 5-year average forward P/E of -3.28. For a more detailed relative valuation and DCF analysis to assess ADC Therapeutics SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.28

Current PE

-3.13

Overvalued PE

-0.53

Undervalued PE

-6.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.29

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.39

Undervalued EV/EBITDA

-6.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.05

Current PS

5.57

Overvalued PS

28.04

Undervalued PS

-5.94

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ADCT News & Events

Events Timeline

No data

News

9.5

01-08Newsfilter

ADC Therapeutics Reports $73M Net Revenue for 2025 with Strong Cash Position

7.0

01-08PRnewswire

ADC Therapeutics Faces Securities Fraud Claims, Stock Drops 14.13%

1.0

01-08PRnewswire

ADC Therapeutics CEO Ameet Mallik to Present at J.P. Morgan Healthcare Conference on January 15, 2026

People Also Watch

Frequently Asked Questions

What is ADC Therapeutics SA (ADCT) stock price today?

The current price of ADCT is 3.66 USD — it has increased 2.52 % in the last trading day.

What is ADC Therapeutics SA (ADCT)'s business?

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

What is the price predicton of ADCT Stock?

What is ADC Therapeutics SA (ADCT)'s revenue for the last quarter?

ADC Therapeutics SA revenue for the last quarter amounts to 16.43M USD, decreased -11.03 % YoY.

What is ADC Therapeutics SA (ADCT)'s earnings per share (EPS) for the last quarter?

ADC Therapeutics SA. EPS for the last quarter amounts to -0.36 USD, decreased -14.29 % YoY.

What changes have occurred in the market's expectations for ADC Therapeutics SA (ADCT)'s fundamentals?

How many employees does ADC Therapeutics SA (ADCT). have?

ADC Therapeutics SA (ADCT) has 263 emplpoyees as of January 10 2026.

What is ADC Therapeutics SA (ADCT) market cap?

Today ADCT has the market capitalization of 453.39M USD.